Rituximab

Generic Name
Rituximab
Brand Names
MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
Drug Type
Biotech
Chemical Formula
-
CAS Number
174722-31-7
Unique Ingredient Identifier
4F4X42SYQ6
Background

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication

Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
Associated Therapies
-
Clinical Trials
Related News

Epcoritamab and Rituximab for First-line Follicular Lymphoma

First Posted Date
2023-03-24
Last Posted Date
2024-07-10
Lead Sponsor
Reid Merryman, MD
Target Recruit Count
35
Registration Number
NCT05783609
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy

First Posted Date
2023-03-24
Last Posted Date
2023-03-24
Lead Sponsor
Beijing Friendship Hospital
Target Recruit Count
2
Registration Number
NCT05782933
Locations
🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, China

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

First Posted Date
2023-03-21
Last Posted Date
2023-03-21
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
30
Registration Number
NCT05777369

Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial

First Posted Date
2023-02-21
Last Posted Date
2023-08-25
Lead Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Target Recruit Count
80
Registration Number
NCT05734794
Locations
🇨🇳

Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

First Posted Date
2023-02-21
Last Posted Date
2024-11-27
Lead Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Target Recruit Count
120
Registration Number
NCT05735834
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇫🇷

Institut Bergonié, Bordeaux, France

and more 51 locations

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

First Posted Date
2023-02-21
Last Posted Date
2024-10-21
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
150
Registration Number
NCT05735717
Locations
🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

First Posted Date
2023-02-21
Last Posted Date
2024-05-09
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
24
Registration Number
NCT05736419
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

and more 3 locations

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

First Posted Date
2023-01-26
Last Posted Date
2024-06-17
Lead Sponsor
Tong Chen, MD
Target Recruit Count
30
Registration Number
NCT05698147
Locations
🇨🇳

Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

The First Affiliated Hospital Of Fujian Medical University, Fuzhou, Fujian, China

and more 2 locations

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

First Posted Date
2023-01-25
Last Posted Date
2024-04-25
Lead Sponsor
Cerium Pharmaceuticals, Inc.
Target Recruit Count
148
Registration Number
NCT05696613
Locations
🇺🇸

Valiance Clinical Research, Tarzana, California, United States

🇮🇳

KLE Hospital, Belgaum, Karnataka, India

🇺🇸

University of Iowa, Iowa City, Iowa, United States

and more 28 locations

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

First Posted Date
2023-01-19
Last Posted Date
2023-01-19
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
169
Registration Number
NCT05690191
Locations
🇨🇳

Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy